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Abstract 
Purpose: Occurrence of choroidal neovascularization (CNV) during pregnancy has been 
reported as a complication of presumed ocular histoplasmosis syndrome or punctuate 
inner chorioretinopathy. To our knowledge, idiopathic CNV (ICNV) during pregnancy has 
only been reported once in the relevant literature. Bevacizumab has been used for the 
treatment of ICNV in small case series. However, there is limited experience regarding 
the use of ranibizumab for the management of ICNV.  
Case Report: A 31-year-old woman in the eighth month of her second pregnancy was 
diagnosed with mild macular and papillary edema. She was followed up using 
biomicroscopy, fluorescein angiography (FA), and optical coherence tomography (OCT). 
After 3 months, visual acuity further deteriorated and funduscopy, FA and OCT findings 
revealed a juxtapapillary choroidal neovascular membrane (CNVM). After two 
ranibizumab injections, best-corrected visual acuity increased significantly, physiological 
macular anatomy was restored and no subretinal fluid was observed.  
Discussion: In this case report, we present a young pregnant patient with peripapillary 
ICNV and neurosensory detachment involving the macula, and treatment of the eye with 
intravitreal ranibizumab following uneventful delivery. Increased angiogenic factor levels 
associated with pregnancy may contribute to the onset of CNV although this relationship 
has to be investigated experimentally. The rapid response to ranibizumab suggests that 
this anti-VEGF agent may be an alternative treatment option in the management of 
peripapillary ICNV. Case Rep Ophthalmol 2011;2:129–133 
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Introduction 
Several ocular conditions have been reported to be influenced by pregnancy. This is 
attributed to hormonal alterations, changing hemodynamic parameters and increased 
expression of angiogenic growth factors associated with gestation [1]. These events may 
affect retinal pigment epithelium and the physiology of the choriocapillaris and 
potentially increase the risk of choroidal neovascularization (CNV) development. 
CNV occurrence during pregnancy has been reported as a complication of presumed 
ocular histoplasmosis syndrome [1] or punctuate inner chorioretinopathy [2]. To our 
knowledge, idiopathic CNV (ICNV) during pregnancy has only been reported once in the 
relevant literature [1]. Bevacizumab has been used for the treatment of ICNV in small 
case series [3, 4]. However, there is limited experience regarding ranibizumab use for the 
management of ICNV. We report a case of peripapillary ICNV and its treatment with 
intravitreal ranibizumab in a healthy, young, pregnant woman.  
Case Report 
A 31-year-old woman in the eighth month of her second pregnancy was referred to our clinic for 
blurred vision OD. Ophthalmic history was unremarkable. She reported one previous uncomplicated 
pregnancy. Best-corrected visual acuity (BCVA) was 20/25 OD, 20/20 OS, with no metamorphopsia 
OU. Fundoscopy OD revealed mild macular and papillary edema and a slightly elevated optic disc OS. 
The patient had neither proteinuria nor hypertension, and pre-eclampsia was excluded. Because of her 
pregnancy, fluorescein angiography (FA) was not performed. As BCVA was minimally decreased, no 
intervention and frequent follow-ups were recommended. After uneventful labor, an infant with no 
significant health problems was delivered. Two months later, lactation was stopped. 
Three months after her last ophthalmic examination, BCVA was 20/32 with metamorphopsia OD 
and 20/20 OS. Fundoscopy revealed a serous neurosensory detachment in the papillomacular region 
that involved the fovea and subretinal hemorrhage inferotemporally of the disc OD, but no significant 
findings OS. FA and optical coherence tomography (OCT) scans showed a juxtapapillary choroidal 
neovascular membrane (CNVM) OD, but observation was again considered sufficient, given the 
acceptable BCVA level. A month later  BCVA was 20/50 OD and subretinal fluid (SRF) was increased. 
This observation was confirmed by OCT and indocyanine green (ICG) angiography (fig. 1). Intravitreal 
ranibizumab treatment was discussed with and accepted by the patient. BCVA improved 1 week (20/32) 
and 1 month after the first injection (20/25). FA showed decreased CNVM size and peripapillary 
leakage. OCT confirmed restoration of physiological macular anatomy with a small, shallow 
peripapillary neurosensory detachment. Due to persistent SRF, a second ranibizumab injection was 
performed. One month after the second injection, BCVA was 20/20 with slight metamorphopsia. A 
small quantity of residual peripapillary SRF and initiation of scarring in the papillomacular region were 
observed. Two months after the second injection, BCVA was 20/20 with slight metamorphopsia and no 
SRF (fig. 2). 
Discussion 
Vascular endothelial growth factor (VEGF) is regarded as the primary regulator of 
angiogenesis. After conception, VEGF and placental growth factor (PlGF) are highly 
expressed in the placenta, and can be detected in the maternal circulation throughout 
pregnancy [5]; findings which are possibly indicative of a role in the pathogenesis of 
pregnancy-associated ocular CNVM as presented in this case.  Case Rep Ophthalmol 2011;2:129–133 
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The Macular Photocoagulation Study Group proposed argon laser photocoagulation in 
patients with extrafoveal ICNV, excluding those located in the papillomacular bundle [6]. 
ICNV is not necessarily associated with marked visual deterioration and its prognosis in 
young patients that have not received any treatment is often good [7], favoring a 
conservative treatment strategy. In our case, intravitreal ranibizumab administration was 
based on previous reports of anti-VEGF effectiveness regarding BCVA improvement and 
macular edema reduction in elderly patients with idiopathic CNV [3, 4]. As there are no 
anti-VEGF treatment guidelines for peripapillary ICNV in young patients, continuation 
of treatment was decided based on rapid BCVA deterioration as well as funduscopic, FA 
and OCT findings [3, 4].  
In this case report, we present a young pregnant patient with peripapillary ICNV and 
neurosensory detachment involving the macula. It is possible that increased angiogenic 
factor levels associated with pregnancy may contribute to the onset of CNV, although this 
relationship has to be investigated experimentally. The safety and efficacy of ranibizumab 
in this context is yet to be determined in a large series of patients. However, the rapid 
response to this anti-VEGF agent in our case (within 1 week from the first injection) 
suggests that it may be an alternative treatment option in the management of pregnancy-
associated peripapillary ICNV. 
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Fig. 1. FA, ICG angiography and OCT of the right eye after uneventful delivery. a Red-free image. 
Serous neurosensory detachment in the papillomacular region, involving the fovea and a localized area 
of subretinal hemorrhage inferotemporally of the optic disc. b FA, early phase. A hyperfluorescent, well-
defined juxtapapillary CNVM is shown. c FA, late phase. Fluorescein pooling and staining of the 
neovascular complex can be observed. d ICG, early phase. A hypofluorescent lesion is depicted. e ICG, 
late phase. Staining of the neovascular complex with leakage in the subretinal space. f OCT revealing a 
neurosensory detachment with an adjacent area of high reflectance indicating juxtapapillary type II 
CNV. 
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Fig. 2. FA and OCT of the right eye 1 month after the first intravitreal ranibizumab injection. a Red-
free image. Resolution of the neurosensory detachment. A ring of hard exudates surrounds the temporal 
rim of the disc. b FA. Reduction in size of the neovascular complex. c FA, late phase. Decreased 
peripapillary leakage. d OCT confirming restoration of the physiological macular anatomy with a small 
remaining area of reflectance next to the optic disc and an adjacent shallow neurosensory detachment 
surrounding the lesion. 
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